Contact Us
Oxford Vacmedix UK
Effective immunotherapy for all patient types
With our unique recombinant overlapping peptide (ROP) platform we aim to make safe, highly efficacious immunotherapies that are HLA unrestricted, applicable to a wide range of cancers and available to as many patients as possible.

Recombinant Overlapping Peptides (ROP)

Novel technology invented by Professor Shisong Jiang
Find Out More

Investor Information

Seeking investment for Phase 2 clinical trials (OVM-200) and Phase 1 clinical trials (OVM-100)
Find Out More

Pipeline - a rich mix of clinical & development assets

Future developments and research being explored incl mRNA delivery
Find Out More
Redefining personalised medicine

Our vision for cancer therapeutics

University of Oxford technology
AdobeStock_289020615 Patient hands_sm
Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy. The Oxford Vacmedix ROP technology has a unique dual mode of action which significantly enhances the immunogenicity of the vaccines and is applicable for all HLA types. This completely new proprietary approach to immunotherapy redefines the definition of personalised medicine. ROP vaccines promise effective treatment of cancer, making it easier to deliver and much more economical than existing personalised medicine.
Novel technology significantly enhances the immunogenicity of peptide vaccines.
"Personalised medicine redefined"
Safety and immunogenicity of TSA with the simplicity of TAA
Applicable to Multiple Tumour Types
Survivin (SVN) is a tumour-associated antigen highly expressed in c90% of cancers
1
Tests & PatientsnServed In 2022
1
Free Patient VisitsnDone Each Month
1+
Specialized Centers nIn 24 States
1%
Client SatisfactionnRate For Services
Nurse reassuring patient
No Serious Adverse Events (SAEs)
Strong Immune Response
Dual Mode of Action

Ongoing UK Phase 1 clinical trial with strong preliminary data

Our lead therapeutic agent, OVM-200, is in clinical trials in the UK. It is being used at leading hospitals to treat patients with advanced Non small cell lung cancer, ovarian cancer and prostate cancer. Initial results show excellent safety and a very strong immune response for both T-cells and antibodies – the dual mode of action.

Our Edge - Recombinant Overlapping Peptides (ROPs):
AdobeStock_1290336709 Lab scientist_sm
Excellent safety profile
Strong immune response
Dual mode of action
Our vision for cancer therapeutics:- with our unique ROP platform we aim to make safe, highly efficacious immunotherapies that are HLA unrestricted, applicable to many cancers, and available to as many patients as possible
1000_F_1045382807_AaWUFKJpg97rCcIj0aiAZi5LgAZOWYav
No Serious Adverse Events (SAEs)
Strong Immune Response
Dual Mode of Action

Ongoing UK Phase 1 clinical trial with strong preliminary data

Whilst peptide vaccines are a potentially safe, immunogenic cancer treatment option, low efficacy has hindered shared antigen peptide vaccines in clinical trials. Others failed to progress despite good data due to drug complexity.

Our Edge - Recombinant Overlapping Peptides (ROPs):
1000_F_1290336709_tJyPcsv3fmUUPImzL6T9tX2CK6ixOhyL
Excellent safety profile
Strong humoral response
Strong cell-mediated response
Our vision for cancer therapeutics:- with our unique ROP platform we aim to make safe, highly efficacious immunotherapies that are HLA unrestricted, applicable to various cancers, are accessible off-the-shelf and available to as many patients as possible.
Novel Technology
1000_F_53644926_0mvUCIxCCTvIa7BAIFuUa3xsaNA9lbeb
The Science of Recombinant Overlapping Peptides (ROPs)
Oxford Vacmedix has created a universal, off-the-shelf vaccine that targets the immune system to tumor cells in over 90 percent of cancers.
In this video, we demonstrate how the ROP-Survivin Vaccine teaches the immune system to fight cancer.
Find Out More
Stay up-to-date with our progress

News & Articles

cms-header-icon-molecule

University of Oxford Spinout

A spinout from the University of Oxford, Oxford Vacmedix UK (OVM) is a clinical-stage biopharma developing advanced therapeutic cancer vaccines.

University of Oxford logo

University of Oxford Spinout

A spinout from the University of Oxford, Oxford Vacmedix UK (OVM) is a clinical-stage biopharma developing advanced therapeutic cancer vaccines.
Helping To Deliver Answers For Health Questions!

Fixed Commitment To Excellence And Quality Of Our Test Results.

The insights we gain through testing then fuel our drug development practice, by identifying patterns and even individuals who might benefit from enrollment in specific drug trials. nnWith the support of our diagnostics capabilities to deliver drug trials that are both reliable.
Values and Culture

Improving Your Health

Partnering for Through our investment in new high volume chemistry tech, we have brought next generation.

Innovations In Vaccines

In the face of a growing street drug crisis, we need quick and accurate screening is a matter of life and death.

Better Health Outcomes

Building a healthier world clearly means looking at the future genetics and being ready for using it.

Trust Shared Purpose

We care for our patients, each other and our communities and excellence is the standard of working quality.
Stay up-to-date with our progress

News & Articles

AdobeStock_289020615 Patient hands_sm
Company News

Patient recruitment completed in OVM-200 Phase 1 trial

The Phase 1 trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been fully recruited in only three months since the new extended dosing protocol was implemented. Oxford...
Sarah Cannon Research Institute
Company News

First patient treated with new extended dosing of OVM-200 cancer vaccine

Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK - 20th February 2025...
Oxford Vacmedix, OVM logo
Company News

Oxford Vacmedix announces major milestone for lead cancer vaccine OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable and sterile four years post manufacture – a major milestone for OVM-200 developm...
NP-800x800-photo-Jan-25
Company News

Oxford Vacmedix appoints Dr Nam Park as Chief Business Officer

The appointment of Dr Nam Park as Chief Business Officer brings further expertise in venture financing and capital markets to Oxford Vacmedix Oxford, UK - 16th January 2025 Pr...
Oxford Vacmedix UK
Company News

Innovate UK award to OVM for clinical development of OVM-200

Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Press Release - In...
Oxford Vacmedix UK
Company News

Oxford Vacmedix licenses OVM-200 to Dx&Vx for South Korea, India and China

Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK - 13th December 2024 Press release -...
en_GBEnglish
en_GBEnglish